Eventide Asset Management LLC Acquires Shares of 2,549,019 Immix Biopharma, Inc. $IMMX

Eventide Asset Management LLC acquired a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,549,019 shares of the company’s stock, valued at approximately $13,331,000. Eventide Asset Management LLC owned about 4.81% of Immix Biopharma as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IMMX. Allworth Financial LP bought a new position in shares of Immix Biopharma during the 4th quarter worth $30,000. Mathes Company Inc. bought a new position in shares of Immix Biopharma during the 4th quarter worth $56,000. Velan Capital Investment Management LP grew its position in shares of Immix Biopharma by 40.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after buying an additional 10,000 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Immix Biopharma by 37.4% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares in the last quarter. Finally, Imprint Wealth LLC bought a new position in shares of Immix Biopharma during the 3rd quarter worth $141,000. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Price Performance

Shares of NASDAQ IMMX opened at $8.45 on Monday. The stock has a market capitalization of $459.76 million, a P/E ratio of -9.18 and a beta of 0.11. Immix Biopharma, Inc. has a 1-year low of $1.94 and a 1-year high of $11.61. The business has a fifty day moving average price of $9.21 and a 200 day moving average price of $7.62.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. As a group, equities research analysts anticipate that Immix Biopharma, Inc. will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on IMMX. Citizens Jmp reissued a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th. HC Wainwright increased their price target on Immix Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Morgan Stanley began coverage on Immix Biopharma in a research report on Wednesday, March 25th. They set an “overweight” rating and a $20.00 price target on the stock. Mizuho increased their price target on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Finally, Wall Street Zen downgraded Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.50.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.